An In-Depth Comparison of Latency-Reversing Agent Combinations in Various and HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression

English version České info

Persistence of latently infected cells during cART is a major hurdle for HIV-1 eradication. A widely proposed strategy to purge these reservoirs involves the reactivation of latent proviruses. The low levels of active P-TEFb and the cytoplasmic sequestration of NF-κB in resting infected cells largely contribute to maintenance of HIV-1 latency. Therefore, utilization of chemical compounds that target both pathways may lead to more potent effects on HIV-1 reactivation than the effect mediated by the individual drug treatments. In this study, we showed that combined treatments of PKC agonists (prostratin, bryostatin-1 and ing-B) with compounds releasing P-TEFb (JQ1, I-BET, I-BET151 and HMBA) exhibited a synergistic increase in viral reactivation from latency. In-depth comparison of combined treatments in various in vitro cellular models of HIV-1 latency as well as in ex vivo primary cell cultures from cART-treated HIV+ aviremic patients identified bryostatin-1+JQ1 and ing-B+JQ1 to potently reactivate latent HIV-1. The potent effects of these two combinations were detected as early as 24 hours post-treatment. Importantly, bryostatin-1 was used at concentrations below the drug plasma levels achieved by doses used in children with refractory solid tumors. Our mechanistic data established a correlation between potentiated P-TEFb activation and potentiated or synergistic (depending on the HIV-1 latency cellular model used) induction of HIV-1 gene expression observed after the combined versus individual drug treatments. In conclusion, our results establish a proof-of-concept for PKC agonists combined with compounds releasing active P-TEFb as a strategy proposed for a cure or a durable remission of HIV infection.

Vyšlo v časopise: An In-Depth Comparison of Latency-Reversing Agent Combinations in Various and HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression. PLoS Pathog 11(7): e32767. doi:10.1371/journal.ppat.1005063
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1005063

Souhrn

Zdroje

1. Smit C, Geskus R, Walker S, Sabin C, Coutinho R, et al. (2006) Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 20 : 741–749. 16514305

2. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, et al. (2003) Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349 : 1993–2003. 14627784

3. Blankson JN, Persaud D, Siliciano RF (2002) The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 53 : 557–593. 11818490

4. Crowe S, Zhu T, Muller WA (2003) The contribution of monocyte infection and trafficking to viral persistence, and maintenance of the viral reservoir in HIV infection. J Leukoc Biol 74 : 635–641. 12960232

5. Lewin SR, Kirihara J, Sonza S, Irving L, Mills J, et al. (1998) HIV-1 DNA and mRNA concentrations are similar in peripheral blood monocytes and alveolar macrophages in HIV-1-infected individuals. AIDS 12 : 719–727. 9619803

6. Bergamaschi A, Pancino G (2010) Host hindrance to HIV-1 replication in monocytes and macrophages. Retrovirology 7 : 31. doi: 10.1186/1742-4690-7-31 20374633

7. Crowe SM, Sonza S (2000) HIV-1 can be recovered from a variety of cells including peripheral blood monocytes of patients receiving highly active antiretroviral therapy: a further obstacle to eradication. J Leukoc Biol 68 : 345–350. 10985250

8. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, et al. (2009) HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med.

9. Maldarelli F, Wu X, Su L, Simonetti FR, Shao W, et al. (2014) HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 345 : 179–183. doi: 10.1126/science.1254194 24968937

10. Chun TW, Davey RT Jr., Ostrowski M, Shawn Justement J, Engel D, et al. (2000) Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med 6 : 757–761. 10888923

11. Saez-Cirion A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, et al. (2013) Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 9: e1003211. doi: 10.1371/journal.ppat.1003211 23516360

12. Colin L, Van Lint C (2009) Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology 6 : 111. doi: 10.1186/1742-4690-6-111 19961595

13. McKernan LN, Momjian D, Kulkosky J (2012) Protein Kinase C: One Pathway towards the Eradication of Latent HIV-1 Reservoirs. Adv Virol 2012 : 805347. doi: 10.1155/2012/805347 22500169

14. Van Lint C, Bouchat S, Marcello A (2013) HIV-1 transcription and latency: an update. Retrovirology 10 : 67. doi: 10.1186/1742-4690-10-67 23803414

15. Bocklandt S, Blumberg PM, Hamer DH (2003) Activation of latent HIV-1 expression by the potent anti-tumor promoter 12-deoxyphorbol 13-phenylacetate. Antiviral Res 59 : 89–98. 12895692

16. Biancotto A, Grivel JC, Gondois-Rey F, Bettendroffer L, Vigne R, et al. (2004) Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue. J Virol 78 : 10507–10515. 15367617

17. Kulkosky J, Culnan DM, Roman J, Dornadula G, Schnell M, et al. (2001) Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 98 : 3006–3015. 11698284

18. Korin YD, Brooks DG, Brown S, Korotzer A, Zack JA (2002) Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J Virol 76 : 8118–8123. 12134017

19. Williams SA, Chen LF, Kwon H, Fenard D, Bisgrove D, et al. (2004) Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem 279 : 42008–42017. 15284245

20. Gulakowski RJ, McMahon JB, Buckheit RW Jr., Gustafson KR, Boyd MR (1997) Antireplicative and anticytopathic activities of prostratin, a non-tumor-promoting phorbol ester, against human immunodeficiency virus (HIV). Antiviral Res 33 : 87–97. 9021050

21. Perez M, de Vinuesa AG, Sanchez-Duffhues G, Marquez N, Bellido ML, et al. (2010) Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency. Curr HIV Res 8 : 418–429. 20636281

22. Mehla R, Bivalkar-Mehla S, Zhang R, Handy I, Albrecht H, et al. (2010) Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS One 5: e11160. doi: 10.1371/journal.pone.0011160 20585398

23. Kollar P, Rajchard J, Balounova Z, Pazourek J (2014) Marine natural products: bryostatins in preclinical and clinical studies. Pharm Biol 52 : 237–242. doi: 10.3109/13880209.2013.804100 24033119

24. Grant S, Roberts J, Poplin E, Tombes MB, Kyle B, et al. (1998) Phase Ib trial of bryostatin 1 in patients with refractory malignancies. Clin Cancer Res 4 : 611–618. 9533528

25. Abreu CM, Price SL, Shirk EN, Cunha RD, Pianowski LF, et al. (2014) Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR. PLoS One 9: e97257. doi: 10.1371/journal.pone.0097257 24827152

26. Jiang G, Mendes EA, Kaiser P, Sankaran-Walters S, Tang Y, et al. (2014) Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cdelta-NF-kappaB signaling. AIDS 28 : 1555–1566. doi: 10.1097/QAD.0000000000000289 24804860

27. Pandelo Jose D, Bartholomeeusen K, da Cunha RD, Abreu CM, Glinski J, et al. (2014) Reactivation of latent HIV-1 by new semi-synthetic ingenol esters. Virology 462–463 : 328–339. doi: 10.1016/j.virol.2014.05.033 25014309

28. Mbonye UR, Wang B, Gokulrangan G, Chance MR, Karn J (2015) Phosphorylation of HEXIM1 at Tyr271 and Tyr274 Promotes Release of P-TEFb from the 7SK snRNP Complex and Enhances Proviral HIV Gene Expression. Proteomics 15 : 2078–2086. doi: 10.1002/pmic.201500038 25900325

29. Karn J, Stoltzfus CM (2012) Transcriptional and posttranscriptional regulation of HIV-1 gene expression. Cold Spring Harb Perspect Med 2: a006916. doi: 10.1101/cshperspect.a006916 22355797

30. Sobhian B, Laguette N, Yatim A, Nakamura M, Levy Y, et al. (2010) HIV-1 Tat assembles a multifunctional transcription elongation complex and stably associates with the 7SK snRNP. Mol Cell 38 : 439–451. doi: 10.1016/j.molcel.2010.04.012 20471949

31. Bartholomeeusen K, Xiang Y, Fujinaga K, Peterlin BM (2012) Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein. J Biol Chem 287 : 36609–36616. doi: 10.1074/jbc.M112.410746 22952229

32. Li Z, Guo J, Wu Y, Zhou Q (2013) The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. Nucleic Acids Res 41 : 277–287. doi: 10.1093/nar/gks976 23087374

33. Brass AL, Dykxhoorn DM, Benita Y, Yan N, Engelman A, et al. (2008) Identification of host proteins required for HIV infection through a functional genomic screen. Science 319 : 921–926. doi: 10.1126/science.1152725 18187620

34. Banerjee C, Archin N, Michaels D, Belkina AC, Denis GV, et al. (2012) BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol 92 : 1147–1154. doi: 10.1189/jlb.0312165 22802445

35. Boehm D, Calvanese V, Dar RD, Xing S, Schroeder S, et al. (2013) BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle 12 : 452–462. doi: 10.4161/cc.23309 23255218

36. Zhu J, Gaiha GD, John SP, Pertel T, Chin CR, et al. (2012) Reactivation of latent HIV-1 by inhibition of BRD4. Cell Rep 2 : 807–816. doi: 10.1016/j.celrep.2012.09.008 23041316

37. Contreras X, Barboric M, Lenasi T, Peterlin BM (2007) HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription. PLoS Pathog 3 : 1459–1469. 17937499

38. Sung TL, Rice AP (2006) Effects of prostratin on Cyclin T1/P-TEFb function and the gene expression profile in primary resting CD4+ T cells. Retrovirology 3 : 66. 17014716

39. Bartholomeeusen K, Fujinaga K, Xiang Y, Peterlin BM (2013) Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription. J Biol Chem 288 : 14400–14407. doi: 10.1074/jbc.M113.464834 23539624

40. Fujinaga K, Barboric M, Li Q, Luo Z, Price DH, et al. (2012) PKC phosphorylates HEXIM1 and regulates P-TEFb activity. Nucleic Acids Res 40 : 9160–9170. doi: 10.1093/nar/gks682 22821562

41. Wires ES, Alvarez D, Dobrowolski C, Wang Y, Morales M, et al. (2012) Methamphetamine activates nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) and induces human immunodeficiency virus (HIV) transcription in human microglial cells. J Neurovirol 18 : 400–410. doi: 10.1007/s13365-012-0103-4 22618514

42. Kutsch O, Vey T, Kerkau T, Hunig T, Schimpl A (2002) HIV type 1 abrogates TAP-mediated transport of antigenic peptides presented by MHC class I. Transporter associated with antigen presentation. AIDS Res Hum Retroviruses 18 : 1319–1325. 12487820

43. Matzuk MM, McKeown MR, Filippakopoulos P, Li Q, Ma L, et al. (2012) Small-molecule inhibition of BRDT for male contraception. Cell 150 : 673–684. 22901802

44. Spina CA, Anderson J, Archin NM, Bosque A, Chan J, et al. (2013) An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog 9: e1003834. doi: 10.1371/journal.ppat.1003834 24385908

45. Cillo AR, Sobolewski MD, Bosch RJ, Fyne E, Piatak M Jr., et al. (2014) Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 111 : 7078–7083. doi: 10.1073/pnas.1402873111 24706775

46. Pavlick AC, Wu J, Roberts J, Rosenthal MA, Hamilton A, et al. (2009) Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors. Cancer Chemother Pharmacol 64 : 803–810. doi: 10.1007/s00280-009-0931-y 19221754

47. Morgan RJ Jr., Leong L, Chow W, Gandara D, Frankel P, et al. (2012) Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study. Invest New Drugs 30 : 723–728. doi: 10.1007/s10637-010-9557-5 20936324

48. Liu P, Xiang Y, Fujinaga K, Bartholomeeusen K, Nilson KA, et al. (2014) Release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein (snRNP) activates hexamethylene bisacetamide-inducible protein (HEXIM1) transcription. J Biol Chem 289 : 9918–9925. doi: 10.1074/jbc.M113.539015 24515107

49. Fujinaga K, Luo Z, Schaufele F, Peterlin BM (2015) Visualization of positive transcription elongation factor b (P-TEFb) activation in living cells. J Biol Chem 290 : 1829–1836. doi: 10.1074/jbc.M114.605816 25492871

50. Budhiraja S, Famiglietti M, Bosque A, Planelles V, Rice AP (2013) Cyclin T1 and CDK9 T-loop phosphorylation are downregulated during establishment of HIV-1 latency in primary resting memory CD4+ T cells. J Virol 87 : 1211–1220. doi: 10.1128/JVI.02413-12 23152527

51. Chiang K, Rice AP (2012) MicroRNA-mediated restriction of HIV-1 in resting CD4+ T cells and monocytes. Viruses 4 : 1390–1409. doi: 10.3390/v4091390 23170164

52. Chiang K, Sung TL, Rice AP (2012) Regulation of cyclin T1 and HIV-1 Replication by microRNAs in resting CD4+ T lymphocytes. J Virol 86 : 3244–3252. doi: 10.1128/JVI.05065-11 22205749

53. Hoque M, Shamanna RA, Guan D, Pe'ery T, Mathews MB (2011) HIV-1 replication and latency are regulated by translational control of cyclin T1. J Mol Biol 410 : 917–932. doi: 10.1016/j.jmb.2011.03.060 21763496

54. McNamara RP, McCann JL, Gudipaty SA, D'Orso I (2013) Transcription factors mediate the enzymatic disassembly of promoter-bound 7SK snRNP to locally recruit P-TEFb for transcription elongation. Cell Rep 5 : 1256–1268. doi: 10.1016/j.celrep.2013.11.003 24316072

55. Zou Z, Huang B, Wu X, Zhang H, Qi J, et al. (2014) Brd4 maintains constitutively active NF-kappaB in cancer cells by binding to acetylated RelA. Oncogene 33 : 2395–2404. doi: 10.1038/onc.2013.179 23686307

56. Calao M, Burny A, Quivy V, Dekoninck A, Van Lint C (2008) A pervasive role of histone acetyltransferases and deacetylases in an NF-kappaB-signaling code. Trends Biochem Sci 33 : 339–349. doi: 10.1016/j.tibs.2008.04.015 18585916

57. Cherrier T, Le Douce V, Eilebrecht S, Riclet R, Marban C, et al. (2013) CTIP2 is a negative regulator of P-TEFb. Proc Natl Acad Sci U S A 110 : 12655–12660. doi: 10.1073/pnas.1220136110 23852730

58. Eilebrecht S, Le Douce V, Riclet R, Targat B, Hallay H, et al. (2014) HMGA1 recruits CTIP2-repressed P-TEFb to the HIV-1 and cellular target promoters. Nucleic Acids Res 42 : 4962–4971. doi: 10.1093/nar/gku168 24623795

59. Dar RD, Hosmane NN, Arkin MR, Siliciano RF, Weinberger LS (2014) Screening for noise in gene expression identifies drug synergies. Science 344 : 1392–1396. doi: 10.1126/science.1250220 24903562

60. Spivak AM, Andrade A, Eisele E, Hoh R, Bacchetti P, et al. (2014) A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis 58 : 883–890. doi: 10.1093/cid/cit813 24336828

61. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, et al. (2012) Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487 : 482–485. doi: 10.1038/nature11286 22837004

62. Kumar A, Abbas W, Herbein G (2014) HIV-1 latency in monocytes/macrophages. Viruses 6 : 1837–1860. doi: 10.3390/v6041837 24759213

63. Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF (2014) New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 20 : 425–429. doi: 10.1038/nm.3489 24658076

64. Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, et al. (2013) Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155 : 540–551. doi: 10.1016/j.cell.2013.09.020 24243014

65. Reuse S, Calao M, Kabeya K, Guiguen A, Gatot JS, et al. (2009) Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One 4: e6093. doi: 10.1371/journal.pone.0006093 19564922

66. Bouchat S, Gatot JS, Kabeya K, Cardona C, Colin L, et al. (2012) Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients. AIDS 26 : 1473–1482. doi: 10.1097/QAD.0b013e32835535f5 22555163

67. Hezareh M, Moukil MA, Szanto I, Pondarzewski M, Mouche S, et al. (2004) Mechanisms of HIV receptor and co-receptor down-regulation by prostratin: role of conventional and novel PKC isoforms. Antivir Chem Chemother 15 : 207–222. 15457682

68. Weitman S, Langevin AM, Berkow RL, Thomas PJ, Hurwitz CA, et al. (1999) A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study. Clin Cancer Res 5 : 2344–2348. 10499603

69. Lebwohl M, Shumack S, Stein Gold L, Melgaard A, Larsson T, et al. (2013) Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol 149 : 666–670. doi: 10.1001/jamadermatol.2013.2766 23553119

70. Tang Y, Gholamin S, Schubert S, Willardson MI, Lee A, et al. (2014) Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat Med 20 : 732–740. doi: 10.1038/nm.3613 24973920

71. Venkataraman S, Alimova I, Balakrishnan I, Harris P, Birks DK, et al. (2014) Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget 5 : 2355–2371. 24796395

72. Belkina AC, Nikolajczyk BS, Denis GV (2013) BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. J Immunol 190 : 3670–3678. doi: 10.4049/jimmunol.1202838 23420887

73. Deng K, Pertea M, Rongvaux A, Wang L, Durand CM, et al. (2015) Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517 : 381–385. doi: 10.1038/nature14053 25561180

74. Laird GM, Bullen CK, Rosenbloom DI, Martin AR, Hill AL, et al. (2015) Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest 125 : 1901–1912. doi: 10.1172/JCI80142 25822022

75. Avettand-Fenoel V, Chaix ML, Blanche S, Burgard M, Floch C, et al. (2009) LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01). J Med Virol 81 : 217–223. doi: 10.1002/jmv.21390 19107966